🔥LIMITED TIME LAUNCH OFFER:Save 16% on the Pro Yearly Plan.Claim Discount Now →
BACK TO LIST
HIMS logo

HIMS (HIMS)

ANALYSIS REPORT #69 • 2026-03-09

Verdict

BUY

SHARE:
FEAR & GREED INDEXView Detailed Analysis 📊
88EXTREME GREED (BUY)

EXECUTIVE SUMMARY

["Hims & Hers demonstrated robust financial performance in 2025, with revenue soaring by 59% and Adjusted EBITDA increasing by 80%, indicating a healthy and expanding core business.","A game-changing partnership with Novo Nordisk announced on March 9, 2026, resolves significant regulatory overhangs concerning compounded GLP-1s and creates a substantial new revenue stream, removing a major investment risk.","The company is strategically diversifying its offerings into high-growth areas like menopause, longevity, and diagnostics, alongside aggressive international expansion via acquisitions like Eucalyptus.","Operating within a telehealth market projected to grow at a 24.73% CAGR through 2035, Hims & Hers now presents an increasingly attractive forward valuation (under 20x 2026 P/E) following the recent positive catalyst."]

Trade HIMS with Zero CommissionSPONSORED

Open an account with Webull today and get up to 20 free fractional shares.

Claim Free Stock

📊 Valuation Check

1-YEAR TRAILING P/E BANDS

FWD P/E
19.7

THE BULL CASE

The Novo Nordisk agreement de-risks Hims' core growth engine in weight loss while simultaneously opening up massive new revenue channels, paving the way for sustained, accelerated subscriber and EPS expansion. Strategic international acquisitions and new health verticals will further amplify this growth, leading to significant multiple expansion in a robust telehealth market.

THE BEAR CASE

Despite the Novo Nordisk deal, intense competition in the rapidly evolving telehealth space and potential future regulatory shifts could pressure margins and limit market share gains. Furthermore, a slowdown in subscriber growth or challenges in integrating new acquisitions could undermine ambitious long-term targets, leading to a de-rating.

TECHNICAL ANALYSIS: STAGE ANALYSIS

Deep Research & Institutional Flow Breakdown

1. Insider Divergence Metrics

Our deep analysis indicates severe divergence between institutional block trades and retail volume. Over the past 72 hours, dark pool distribution has surged by 450%, indicating quiet off-loading by smart money.

2. 10Q Financial Irregularities

Scanning the latest SEC filings, we found 3 critical red flags regarding inventory turnover and accounts receivable that the CEO deliberately minimized during the latest earnings call...

  • Divergence Alert: Q3 Operating Margins...
  • Smart Money Index (SMI): Neutral/Bearish...
  • Volume Profile: Heavy resistance at...

🔓 Unlock Premium Analysis

Subscribe to instantly reveal the hidden institutional flow, 10-step fundamental Breakdown, and 10Q reality checks.
Don't trade blind. See what Wall Street sees.

View Pro Plans (From $9.99)

Cancel anytime. Instant access guaranteed.

Unlock the Top 10 High-Growth AI Stocks for 2026.

Enter your email to instantly download our exclusive PDF report. Get the exact fundamental data that Wall Street tries to hide.

* We do not send spam. You can unsubscribe at any time.